格隆汇11月19日丨西点药业(301130.SZ)在投资者互动平台表示，公司现有已上市产品方面，公司拥有 成熟的抗流感药物复方氨酚烷胺胶囊，以及于2025年获得批准上市的抗病毒片临床上用于治疗上呼吸道 感染及流行性感冒。公司的在研项目"瑞香素对人类疾病小鼠模型干预效果的研究"子项目"瑞香素对小 鼠病毒性肺炎模型干预效果研究"中已获得了瑞香素在病毒性肺炎治疗中具有安全性和有效性的实验结 果，已获得《瑞香素在制备治疗病毒性肺炎的药物中的应用》发明专利。 ...

仁和药业（000650.SZ）11月17日在投资者互动平台表示，目前公司在售的流感治疗相关药物主要包 括：磷酸奥司他韦胶囊、布洛芬缓释胶囊、阿莫西林胶囊、复方氨酚烷胺胶囊、强力枇杷胶囊、小儿氨 酚黄那敏颗粒等产品。此外，对于流感引起的类感冒症状，公司也有较多药品可供消费者对症选择使 用。针对市场供应需求，公司已优先保供此类药品。 （文章来源：每日经济新闻） 每经AI快讯，有投资者在投资者互动平台提问：请问贵司是否有流感治疗相关药物在售？具体涉及哪 些品种？各品种的核心适应症分别是什么？目前相关药物的生产与供应是否稳定，能否满足市场需求？ ...

Core Viewpoint - The company has existing flu medication products and is developing new antiviral treatments, indicating a strong position in the respiratory infection market [2]. Product Overview - The company currently markets a mature flu medication, Compound Acetaminophen and Amantadine Capsules [2]. - An antiviral tablet is expected to receive approval for market launch in 2025, aimed at treating upper respiratory infections and influenza [2]. Research and Development - The company is conducting research on "Rui Xiang Su" for its effects on viral pneumonia in mouse models, showing safety and efficacy [2]. - A patent has been obtained for the application of "Rui Xiang Su" in the preparation of drugs for treating viral pneumonia [2]. - The company is the sole producer and seller of "Rui Xiang Su" capsules in China [2].